Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW679769 in fibromyalgia syndrome with comorbid depression
2005-001010-41Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vercirnon in fibromyalgia (FM) and major depressive disorder (MDD) (2 arms), sponsored by GSK. Started Jan 2006; status: terminated.
02
Drugs
vercirnon
03
Conditions
fibromyalgia (FM)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-001010-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001010-41.